{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T03:38:02Z","timestamp":1784950682897,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007154","name":"Wake Forest University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007154","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Cytoreductive surgery-hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) candidates often have extraperitoneal abdominal disease. Current expert peritoneal surface malignancy (PSM) guidelines recommend that the presence of extraperitoneal disease is a contraindication to CRS-HIPEC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted a retrospective review of our institutional appendiceal and colorectal CRS-HIPEC registries. Two study cohorts were constructed: (1) cytoreduction with extraperitoneal abdominal disease, and (2) cytoreductions limited to peritoneal structures alone. The primary study outcome was survival. Subgroup analysis was based on the primary tumor and completeness of cytoreduction.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Overall, 864 CRS-HIPEC cases were evaluated, consisting of 578 appendiceal primaries and 286 colorectal cancers. The extraperitoneal cohort included 101 patients, with 763 patients in the non-extraperitoneal group. The median follow-up time was 13.18 years. The main analysis showed no significant differences in survival times. For\u00a0overall\u00a0survival (OS)  there was a\u00a0mean OS time\u00a0of 5.87\u00a0years and a median OS time\u00a0of 4.43 years for extraperitoneal cytoreductions compared with a mean of 5.90\u00a0years and a median of 4.76 years for non-extraperitoneal cytoreductions (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.955). Five-year OS rates did not differ at 49.1% versus 49.5% (odds ratio [OR] 1.036, 95% confidence interval [CI] 0.671\u20131.597, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.874). Disease-free survival (DFS) times showed a mean of 4.40 years and a median of 1.93 years for extraperitoneal cases versus a mean of 5.44\u00a0years and a median of 3.05 years for non-extraperitoneal cases (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.210). Five-year DFS rates also showed no differences (OR 0.894, 95% CI 0.476\u20131.681, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.728). No significant differences in progression-free survival\u00a0(PFS)Pp times (<jats:italic>p<\/jats:italic>\u00a0=\u00a00.061) were reported. Multivariate Cox regression analysis indicated that extraperitoneal CRS was not an independent predictor of OS (hazard ratio [HR] 1.281, 95% CI 0.885\u20131.854, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.190), DFS (HR 1.087, 95% CI 0.694\u20131.701, <jats:italic>p<\/jats:italic>\u00a0=\u00a00.716), or PFS (HR 0.650, 95% CI 0.243\u20131.738).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>We conducted the largest analysis evaluating extraperitoneal cytoreductions, with no significant differences in almost all survival outcomes. We propose that the presence of extraperitoneal abdominal disease is not a contraindication to proceeding with CRS-HIPEC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1245\/s10434-024-16866-6","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T16:23:21Z","timestamp":1738686201000},"page":"2893-2902","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) of Extraperitoneal Abdominal Disease, is it Appropriate?"],"prefix":"10.1245","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0633-9454","authenticated-orcid":false,"given":"Christopher W.","family":"Mangieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos I.","family":"Votanopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"issue":"20","key":"16866_CR1","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","volume":"21","author":"VJ Verwaal","year":"2003","unstructured":"Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737\u201343.","journal-title":"J Clin Oncol"},{"key":"16866_CR2","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","volume":"15","author":"VJ Verwaal","year":"2008","unstructured":"Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426\u201332.","journal-title":"Ann Surg Oncol"},{"key":"16866_CR3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejca.2015.09.017","volume":"53","author":"PH Cashin","year":"2016","unstructured":"Cashin PH, Mahteme H, Sp\u00e5ng N, et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. Eur J Cancer. 2016;53:155\u201362.","journal-title":"Eur J Cancer"},{"issue":"2","key":"16866_CR4","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256\u201366.","journal-title":"Lancet Oncol"},{"issue":"4","key":"16866_CR5","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/jso.26759","volume":"125","author":"CW Mangieri","year":"2022","unstructured":"Mangieri CW, Moaven O, Valenzuela CD, et al. Utility of hyperthermic intraperitoneal chemotherapy in cases of incomplete cytoreductive surgery. J Surg Oncol. 2022;125(4):703\u201311.","journal-title":"J Surg Oncol"},{"issue":"1","key":"16866_CR6","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1245\/s10434-022-12392-5","volume":"30","author":"CW Mangieri","year":"2023","unstructured":"Mangieri CW, Valenzuela CD, Solsky IB, et al. Switching perfusion agents for repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: surgical dogma or evidence-based practice? Ann Surg Oncol. 2023;30(1):384\u201391.","journal-title":"Ann Surg Oncol"},{"key":"16866_CR7","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.992030","volume":"12","author":"CW Mangieri","year":"2022","unstructured":"Mangieri CW, Levine EA. Management of peritoneal surface metastases from colorectal cancer: cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, pressurized intraperitoneal chemotherapy, and beyond. Front Oncol. 2022;12:992030.","journal-title":"Front Oncol"},{"key":"16866_CR8","volume":"2012","author":"PH Sugarbaker","year":"2012","unstructured":"Sugarbaker PH, Chang D, Stuart OA. Hyperthermic intraoperative thoracoabdominal chemotherapy. Gastroenterol Res Pract. 2012;2012:623417.","journal-title":"Gastroenterol Res Pract"},{"issue":"5","key":"16866_CR9","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/jso.21230","volume":"99","author":"TC Chua","year":"2009","unstructured":"Chua TC, Yan TD, Yap ZL, et al. Thoracic cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy for pseudomyxoma peritonei. J Surg Oncol. 2009;99(5):292\u20135.","journal-title":"J Surg Oncol"},{"key":"16866_CR10","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1245\/s10434-014-3891-3","volume":"21","author":"S Ahmed","year":"2014","unstructured":"Ahmed S, Levine EA, Randle RW, et al. Significance of diaphragmatic resections and thoracic chemoperfusion on outcomes of peritoneal surface disease treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2014;21:4226\u201331.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"16866_CR11","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1245\/s10434-021-10669-9","volume":"29","author":"A Nikiforchin","year":"2022","unstructured":"Nikiforchin A, Gushchin V, Sittig M, et al. Outcomes following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy with and without diaphragmatic resection in patients with peritoneal metastases. Ann Surg Oncol. 2022;29(2):873\u201382.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"16866_CR12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ctrv.2012.11.003","volume":"39","author":"EMV De Cuba","year":"2013","unstructured":"De Cuba EMV, KwakmanKnol RDL, et al. Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: systematic review of all literature and meta-analysis of observational studies. Cancer Treat Rev. 2013;39(4):321\u20137.","journal-title":"Cancer Treat Rev"},{"key":"16866_CR13","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1245\/s10434-016-5543-2","volume":"23","author":"J Navez","year":"2016","unstructured":"Navez J, Remue C, Leonard D, et al. Surgical treatment of colorectal cancer with peritoneal and liver metastases using combined liver and cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: report from a single-centre experience. Ann Surg Oncol. 2016;23:666\u201373.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"16866_CR14","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1053\/j.semtcvs.2008.11.002","volume":"20","author":"AA Mujoomdar","year":"2008","unstructured":"Mujoomdar AA, Sugarbaker DJ. Hyperthermic chemoperfusion for the treatment of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2008;20(4):298\u2013304.","journal-title":"Semin Thorac Cardiovasc Surg"},{"issue":"2","key":"16866_CR15","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3109\/07357907.2011.633292","volume":"30","author":"W-J Chen","year":"2012","unstructured":"Chen W-J, Yuan S-F, Yan Q-Y, et al. Intrapleural chemo-and hyperthermotherapies for malignant pleural effusion: a randomized prospective study. Cancer Investig. 2012;30(2):126\u201330.","journal-title":"Cancer Investig"},{"key":"16866_CR16","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.2147\/CMAR.S170300","volume":"11","author":"LM Enomoto","year":"2019","unstructured":"Enomoto LM, Shen P, Levine EA, et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: patient selection and special considerations. Cancer Manag Res. 2019;11:4231\u201341.","journal-title":"Cancer Manag Res"},{"issue":"2","key":"16866_CR17","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3747\/co.22.2058","volume":"22","author":"P Dub\u00e9","year":"2015","unstructured":"Dub\u00e9 P, Sideris L, Law C, et al. Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms. Curr Oncol. 2015;22(2):100\u201312.","journal-title":"Curr Oncol"},{"issue":"11","key":"16866_CR18","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1002\/cncr.32881","volume":"126","author":"Chicago Consensus Working Group","year":"2020","unstructured":"Chicago Consensus Working Group, et al. The Chicago consensus on peritoneal surface malignancies: management of appendiceal neoplasms. Cancer. 2020;126(11):2525\u201333.","journal-title":"Cancer"},{"issue":"11","key":"16866_CR19","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1002\/cncr.32874","volume":"126","author":"Chicago Consensus Working Group","year":"2020","unstructured":"Chicago Consensus Working Group, et al. The Chicago consensus on peritoneal surface malignancies: management of colorectal metastases. Cancer. 2020;126(11):2534\u201340.","journal-title":"Cancer"},{"issue":"4","key":"16866_CR20","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jamcollsurg.2013.12.013","volume":"218","author":"EA Levine","year":"2014","unstructured":"Levine EA, Stewart JH 4th, Shen P, Russell GB, Loggie BL, Votanopoulos KI. Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. J Am Coll Surg. 2014;218(4):573\u201385.","journal-title":"J Am Coll Surg"},{"issue":"5","key":"16866_CR21","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/jso.23749","volume":"110","author":"S Ahmed","year":"2014","unstructured":"Ahmed S, Stewart JH, Shen P, Votanopoulos KI, Levine EA. Outcomes with cytoreductive surgery and HIPEC for peritoneal metastasis. J Surg Oncol. 2014;110(5):575\u201384.","journal-title":"J Surg Oncol"},{"issue":"2","key":"16866_CR22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4251\/wjgo.v2.i2.68","volume":"2","author":"S Gonz\u00e1lez-Moreno","year":"2010","unstructured":"Gonz\u00e1lez-Moreno S, Gonz\u00e1lez-Bay\u00f3n LA, Ortega-P\u00e9rez G. Hyperthermic intraperitoneal chemotherapy: rationale and technique. World J Gastrointest Oncol. 2010;2(2):68.","journal-title":"World J Gastrointest Oncol"},{"issue":"4","key":"16866_CR23","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jso.21321","volume":"100","author":"M Valle","year":"2009","unstructured":"Valle M, Van der Speeten K, Garofalo A. Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: a multi-institutional retrospective analysis in 52 patients. J Surg Oncol. 2009;100(4):331\u20134.","journal-title":"J Surg Oncol"},{"key":"16866_CR24","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1245\/s10434-013-3224-y","volume":"21","author":"RW Randle","year":"2014","unstructured":"Randle RW, Swett KR, Swords DS, et al. Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. Ann Surg Oncol. 2014;21:1474\u20139.","journal-title":"Ann Surg Oncol"},{"key":"16866_CR25","volume-title":"Tumors of the female pelvic organs","author":"JV Meigs","year":"1934","unstructured":"Meigs JV. Tumors of the female pelvic organs. New York: The Macmillan Co.; 1934."},{"key":"16866_CR26","first-page":"101","volume":"42","author":"CT Griffiths","year":"1975","unstructured":"Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975;42:101\u20134.","journal-title":"Natl Cancer Inst Monogr"},{"key":"16866_CR27","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0002-9610(69)90300-6","volume":"117","author":"RT Long","year":"1969","unstructured":"Long RT, Spratt JS Jr, Dowling E. Pseudomyxoma peritonei. New concepts in management with a report of seventeen patients. Am J Surg. 1969;117:162\u20139.","journal-title":"Am J Surg"},{"key":"16866_CR28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF01274232","volume":"373","author":"PH Sugarbaker","year":"1988","unstructured":"Sugarbaker PH. Surgical management of peritoneal carcinosis: diagnosis, prevention and treatment. Langenbecks Arch Chir. 1988;373:189\u201396.","journal-title":"Langenbecks Arch Chir"},{"key":"16866_CR29","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/978-1-4613-1247-5_20","volume":"82","author":"PH Sugarbaker","year":"1996","unstructured":"Sugarbaker PH. Treatment of peritoneal carcinomatosis from colon or appendiceal cancer with induction intraperitoneal chemotherapy. Cancer Treat Res. 1996;82:317\u201325.","journal-title":"Cancer Treat Res"},{"key":"16866_CR30","first-page":"101","volume":"12","author":"PH Sugarbaker","year":"1985","unstructured":"Sugarbaker PH, Gianola FJ, Speyer JL, et al. Prospective randomized trial of intravenous v intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer. Semin Oncol. 1985;12:101\u201311.","journal-title":"Semin Oncol"},{"key":"16866_CR31","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359\u201374.","journal-title":"Cancer Treat Res"},{"key":"16866_CR32","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jamcollsurg.2017.12.027","volume":"226","author":"EA Levine","year":"2018","unstructured":"Levine EA, Votanopoulos KI, Shen P, Russell G, Fenstermaker J, Mansfield P, Bartlett D, Stewart JH. A multi-center randomized trial to evaluate hematologic toxicities after HIPEC with oxaliplatin or mitomycin in patients with appendiceal tumors. J Am Coll Surg. 2018;226:434\u201345.","journal-title":"J Am Coll Surg"},{"key":"16866_CR33","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1007\/s11605-018-3784-z","volume":"22","author":"JM Cloyd","year":"2018","unstructured":"Cloyd JM, Abdel-Misih S, Hays J, et al. Impact of synchronous liver resection on the perioperative outcomes of patients undergoing CRS-HIPEC. J Gastrointest Surg. 2018;22:1576\u201384.","journal-title":"J Gastrointest Surg"},{"issue":"5","key":"16866_CR34","doi-asserted-by":"crossref","first-page":"828","DOI":"10.21037\/jgo.2018.06.04","volume":"9","author":"TJ Mouw","year":"2018","unstructured":"Mouw TJ, Lu J, Woody-Fowler M, et al. Morbidity and mortality of synchronous hepatectomy with cytoreductive surgery\/hyperthermic intraperitoneal chemotherapy (CRS\/HIPEC). J Gastrointest Oncol. 2018;9(5):828.","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"16866_CR35","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/SLA.0b013e3182778089","volume":"258","author":"L Maggiori","year":"2013","unstructured":"Maggiori L, Go\u00e9r\u00e9 D, Viana B, et al. Should patients with peritoneal carcinomatosis of colorectal origin with synchronous liver metastases be treated with a curative intent? A case-control study. Ann Surg. 2013;258(1):116\u201321.","journal-title":"Ann Surg"},{"issue":"11","key":"16866_CR36","doi-asserted-by":"crossref","first-page":"E167","DOI":"10.1111\/ans.13231","volume":"87","author":"N Alzahrani","year":"2017","unstructured":"Alzahrani N, Ung L, Valle SJ, et al. Synchronous liver resection with cytoreductive surgery for the treatment of liver and peritoneal metastases from colon cancer: results from an Australian centre. ANZ J Surg. 2017;87(11):E167\u201372.","journal-title":"ANZ J Surg"},{"key":"16866_CR37","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1245\/s10434-014-3976-z","volume":"22","author":"AN Doud","year":"2015","unstructured":"Doud AN, Randle RW, Clark CJ, et al. Impact of distal pancreatectomy on outcomes of peritoneal surface disease treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2015;22:1645\u201350.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"16866_CR38","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/SLA.0000000000001225","volume":"263","author":"L Schwarz","year":"2016","unstructured":"Schwarz L, Votanopoulos K, Morris D, et al. Is the combination of distal pancreatectomy and cytoreductive surgery with HIPEC reasonable? Ann Surg. 2016;263(2):369\u201375.","journal-title":"Ann Surg"},{"issue":"5","key":"16866_CR39","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.amjsurg.2020.06.045","volume":"220","author":"BJ Sullivan","year":"2020","unstructured":"Sullivan BJ, Leigh NL, Bekhor EY, et al. Distal pancreatectomy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: identifying risk and improving patient selection. Am J Surg. 2020;220(5):1235\u201341.","journal-title":"Am J Surg"},{"issue":"2","key":"16866_CR40","doi-asserted-by":"crossref","first-page":"104","DOI":"10.17941\/agd.978955","volume":"20","author":"Y \u00d6zg\u00fcn","year":"2021","unstructured":"\u00d6zg\u00fcn Y, \u00d6ter V, Pi\u015fkin E, et al. Effects of distal pancreatectomy and splenectomy on outcomes in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with CC\/0 resection. Akad Gastroenteroloji Derg. 2021;20(2):104\u201311.","journal-title":"Akad Gastroenteroloji Derg"},{"issue":"4","key":"16866_CR41","first-page":"297","volume":"90","author":"\u00d6 D\u00fczg\u00fcn","year":"2019","unstructured":"D\u00fczg\u00fcn \u00d6, Kulal\u0131 F, G\u00f6ret CC, et al. Synchronous pancreas and liver resection during CRS\u00b1HIPEC. Ann Ital Chir. 2019;90(4):297\u2013304.","journal-title":"Ann Ital Chir"},{"key":"16866_CR42","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jss.2022.04.007","volume":"277","author":"EW Beal","year":"2022","unstructured":"Beal EW, Chen JC, Kim A, et al. Is cytoreductive surgery-hyperthermic intraperitoneal chemotherapy still indicated in patients with extraperitoneal disease? J Surg Res. 2022;277:269\u201378.","journal-title":"J Surg Res"},{"issue":"1","key":"16866_CR43","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.clcc.2019.12.002","volume":"19","author":"RM Lee","year":"2020","unstructured":"Lee RM, Zaidi MY, Gamboa AC, et al. What is the optimal preoperative imaging modality for assessing peritoneal cancer index? An analysis from the United States HIPEC Collaborative. Clin Colorectal Cancer. 2020;19(1):e1\u20137.","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"16866_CR44","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ejso.2021.09.014","volume":"48","author":"I van\u2019t Sant","year":"2022","unstructured":"van\u2019t Sant I, Nerad E, Rijsemus CJ, et al. Seeing the whole picture: added value of MRI for extraperitoneal findings in CRS-HIPEC candidates. Eur J Surg Oncol. 2022;48(2):462\u20139.","journal-title":"Eur J Surg Oncol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16866-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-16866-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16866-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T17:27:22Z","timestamp":1741195642000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-16866-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["16866"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-16866-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"29 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}